ANA
LLUCH HERNANDEZ
EMÉRITO/A UNIVERSIDAD
Universitat Autònoma de Barcelona
Barcelona, EspañaPublications en collaboration avec des chercheurs de Universitat Autònoma de Barcelona (22)
2023
-
Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis
Clinical and Translational Oncology, Vol. 25, Núm. 4, pp. 941-958
-
The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review
Clinical and Translational Oncology, Vol. 25, Núm. 2, pp. 417-428
2022
-
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
Science Advances, Vol. 8, Núm. 20
-
The value of sentinel lymph-node biopsy after neoadjuvant therapy: an overview
Clinical and Translational Oncology, Vol. 24, Núm. 9, pp. 1744-1754
2020
-
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 3, pp. 203-213
2018
-
MSK1 regulates luminal cell differentiation and metastatic dormancy in ER + breast cancer
Nature Cell Biology, Vol. 20, Núm. 2, pp. 211-221
-
Erratum to: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer (Nature Cell Biology, (2018), 20, 2, (211-221), 10.1038/s41556-017-0021-z)
Nature Cell Biology
2017
-
Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer
Clinical Cancer Research, Vol. 23, Núm. 22, pp. 7006-7019
2016
-
Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428
-
Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): The SOFT-EST substudy
Journal of Clinical Oncology, Vol. 34, Núm. 14, pp. 1584-1593
2015
-
Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: Results from the GEICAM/2003-10 study
Journal of Clinical Oncology, Vol. 33, Núm. 32, pp. 3788-3795
-
Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer
European Journal of Cancer, Vol. 51, Núm. 12, pp. 1481-1489
-
Patterns of HER2 gene amplification and response to anti-HER2 therapies
PLoS ONE, Vol. 10, Núm. 6
2014
-
Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer
Oncotarget, Vol. 5, Núm. 1, pp. 196-210
-
Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer
European Journal of Cancer, Vol. 50, Núm. 15, pp. 2725-2734
-
Predicting response and survival in chemotherapy-treated triple-negative breast cancer
British Journal of Cancer, Vol. 111, Núm. 8, pp. 1532-1541
-
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: Results from the GEICAM/2006-14 trial
British Journal of Cancer, Vol. 110, Núm. 5, pp. 1139-1147
2013
2012
-
Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer
Annals of Oncology, Vol. 23, Núm. 5, pp. 1156-1164
-
Prospective transGEICAM study of the impact of the 21-gene recurrence score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer
Annals of Oncology, Vol. 23, Núm. 3, pp. 625-631